The Recall Desk

Manufacturer

Attix Pharmaceuticals

470 recalls in our database name Attix Pharmaceuticals as the manufacturing or recalling firm.

What the numbers show

Total
470
Critical
0
Severe
378
Most recent
2015-04-29

Of the 470 recalls from Attix Pharmaceuticals we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 378 (80%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

26–50 of 470

  • SevereFDA (Drugs)·D-671-2015·2015-04-29

    Famciclovir Recalled Due to Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling famciclovir active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Famciclovir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-799-2015·2015-04-29

    Attix Pharmaceuticals Recalls Minocycline HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Minocycline HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Minocycline HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-957-2015·2015-04-29

    Attix Pharmaceuticals Recalls Zinc Pyrithione Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Zinc Pyrithione active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Zinc Pyrithione active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-758-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levofloxacin Hemihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levofloxacin Hemihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Levofloxacin Hemihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-830-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pancuronium Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pancuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Pancuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-761-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levothyroxine Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levothyroxine Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Levothyroxine Sodium (T4) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-886-2015·2015-04-29

    Attix Pharmaceuticals Recalls Roxithromycin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Roxithromycin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Roxithromycin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-841-2015·2015-04-29

    Attix Pharmaceuticals Recalls Phentolamine Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Phentolamine Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Phentolamine Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-954-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vincristine Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vincristine Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Vincristine Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-562-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carboplatin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carboplatin active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Carboplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-727-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ibuprofen Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling ibuprofen active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Ibuprofen active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-859-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pregabalin Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling pregabalin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pregabalin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-643-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxycycline Monohydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Doxycycline Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Doxycycline Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-956-2015·2015-04-29

    Attix Pharmaceuticals Recalls Zidovudine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Zidovudine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Zidovudine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-836-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pentosan Polysulfate Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pentosan Polysulfate Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Pentosan Polysulfate Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-657-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estriol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Estriol active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Estriol (Ultra-Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-818-2015·2015-04-29

    Attix Pharmaceuticals Recalls Nitazoxanide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Nitazoxanide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Nitazoxanide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-926-2015·2015-04-29

    Attix Pharmaceuticals Recalls Thimerosal Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Thimerosal active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Thimerosal active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-856-2015·2015-04-29

    Prednisolone Anhydrous Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Prednisolone Anhydrous active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Prednisolone Anhydrous active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-805-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mometasone Furoate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mometasone Furoate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Mometasone Furoate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-496-2015·2015-04-29

    Attix Pharmaceuticals Recalls DMSA Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling 2,3-Dimercaptosuccinic Acid (DMSA) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    2,3-Dimercaptosuccinic Acid (DMSA) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-625-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dexchlorpheniramine Maleate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dexchlorpheniramine Maleate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dexchlorpheniramine Maleate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-663-2015·2015-04-29

    Attix Pharmaceuticals Recalls Etidronate Disodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Etidronate Disodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Etidronate Disodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-942-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tretinoin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tretinoin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tretinoin or All-Trans Retinoic Acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-675-2015·2015-04-29

    Attix Pharmaceuticals Recalls Flibanserin API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Flibanserin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Flibanserin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide